Using the cost-effectiveness of allogeneic islet transplantation to inform iPSC derived beta cell therapy reimbursement

In the present study a cost-effectiveness analysis of Allogeneic Islet Transplantation was performed and the financial feasibility of a Human Induced Pluripotent Stem Cell (hiPSC) derived Beta Cell therapy was explored. Previously published cost and health benefit data for Islet Transplantation was...

Full description

Saved in:
Bibliographic Details
Main Authors: Peter R.T. Archibald, David J. Williams
Format: Default Article
Published: 2015
Subjects:
Mechanical engineering not elsewhere classified
Reimbursement
Induced pluripotent stem cell
Beta cell
Diabetes
Cost-effectiveness
Allogeneic islet transplantation
Incremental cost-effectiveness ratio
Quality-adjusted life years
Mechanical Engineering not elsewhere classified
Online Access:https://hdl.handle.net/2134/18894
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://hdl.handle.net/2134/18894

Similar Items